Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cerner Co. stock logo
CERN
Cerner
$94.92
$94.92
$69.08
$95.40
$27.92B0.774.00 million shs1,320 shs
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$116.30
$115.72
$60.03
$116.38
$26.63B1.032.50 million shsN/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$98.18
+3.1%
$104.30
$89.92
$122.25
$19.42B0.781.72 million shs3.17 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cerner Co. stock logo
CERN
Cerner
0.00%0.00%0.00%0.00%0.00%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00%0.00%0.00%0.00%0.00%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
+3.11%+8.67%-4.02%-0.96%-19.07%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cerner Co. stock logo
CERN
Cerner
1.4922 of 5 stars
0.00.02.53.90.01.71.3
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.8942 of 5 stars
0.00.00.03.20.01.71.9
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
4.9044 of 5 stars
3.25.02.53.72.42.52.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cerner Co. stock logo
CERN
Cerner
0.00
N/AN/AN/A
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.00
N/AN/AN/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
2.32
Hold$113.4515.55% Upside

Current Analyst Ratings Breakdown

Latest CERN, ZBH, and HZNP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$115.00 ➝ $101.00
5/7/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$140.00 ➝ $125.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$101.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$138.00 ➝ $115.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$120.00 ➝ $104.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$119.00 ➝ $104.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$125.00 ➝ $112.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $95.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$128.00 ➝ $105.00
5/6/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$113.00 ➝ $98.00
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cerner Co. stock logo
CERN
Cerner
$5.76B4.84$5.37 per share17.69$12.56 per share7.56
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$3.63B7.34$7.05 per share16.49$22.38 per share5.20
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$7.70B2.52$12.51 per share7.85$62.67 per share1.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cerner Co. stock logo
CERN
Cerner
$555.60M$1.9947.7027.432.3710.15%22.86%11.75%N/A
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
$521.48M$1.8762.1920.553.9612.02%20.46%11.52%N/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$903.70M$4.5222.0611.071.9511.77%12.99%7.58%N/A

Latest CERN, ZBH, and HZNP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025Q1 2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$1.77$1.81+$0.04$0.91$1.89 billion$1.91 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cerner Co. stock logo
CERN
Cerner
$1.081.14%-20.63%54.27%N/A
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
N/AN/AN/AN/AN/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$0.960.98%N/A21.24%N/A

Latest CERN, ZBH, and HZNP Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/26/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
quarterly$0.240.89%3/31/20253/31/20254/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cerner Co. stock logo
CERN
Cerner
0.41
1.79
1.77
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
0.48
4.27
4.09
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.43
1.91
0.99

Institutional Ownership

CompanyInstitutional Ownership
Cerner Co. stock logo
CERN
Cerner
82.23%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
80.37%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
88.89%

Insider Ownership

CompanyInsider Ownership
Cerner Co. stock logo
CERN
Cerner
0.12%
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2.20%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
1.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cerner Co. stock logo
CERN
Cerner
25,150294.10 million293.75 millionOptionable
Horizon Therapeutics Public Limited stock logo
HZNP
Horizon Therapeutics Public
2,115228.99 million223.96 millionOptionable
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
18,000197.85 million197.18 millionOptionable

Recent News About These Companies

Roth Capital Reduces Earnings Estimates for Zimmer Biomet

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cerner stock logo

Cerner NASDAQ:CERN

Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. It offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. The company also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, it offers a portfolio of clinical and financial healthcare information technology solutions, as well as departmental and care coordination solutions. Further, the company provides tech-enabled services, such as implementation and training, remote hosting, application management, revenue cycle, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, and data-driven services; and complementary hardware and devices for third parties. It serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, free-standing reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. The company was founded in 1979 and is headquartered in North Kansas City, Missouri.

Horizon Therapeutics Public stock logo

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Zimmer Biomet stock logo

Zimmer Biomet NYSE:ZBH

$98.18 +2.97 (+3.12%)
Closing price 05/12/2025 03:59 PM Eastern
Extended Trading
$97.98 -0.19 (-0.20%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.